Genetic modelling of triglyceride-rich lipoprotein/remnant lowering mimics <i>APOC3</i> silencing and predicts clinically relevant coronary heart disease event reductions
Based on our genetic modelling, the degree of TRL/remnant lowering seen on APOC3 silencing would produce a meaningful CHD risk reduction of around 25 % over a 5-year outcomes trial.
Authors
- Chris J. Packard (ORCID: https://orcid.org/0000-0002-2386-9927)
- Anders Gummesson (ORCID: https://orcid.org/0000-0003-0024-960X)
- Martin Adiels (ORCID: https://orcid.org/0000-0002-3667-589X)
- Nicholas J. Leeper (ORCID: https://orcid.org/0000-0002-0905-2806)
- Jan Borén (ORCID: https://orcid.org/0000-0003-0786-8091)
- Elias Björnson (ORCID: https://orcid.org/0000-0002-0003-6463)
- Jennifer Hellawell (ORCID: https://orcid.org/0000-0001-8485-1846)
- Steven E. Nissen
Institutions
- Cleveland Clinic (US)
- Sahlgrenska University Hospital (SE)
- Arrowhead Pharmaceuticals (United States) (US)
- Region Västra Götaland (SE)
- Stanford Medicine (US)
- Center for Clinical Research (United States) (US)
- University of Glasgow (GB)
- University of Gothenburg (SE)
Publication Details
- Journal
- European Journal of Preventive Cardiology
- Published
- 2025-10-13
- DOI
- https://doi.org/10.1093/eurjpc/zwaf657
- Citations
- 4
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 8.03